Market Overview:
The Europe pneumococcal vaccine market size is expected to reach USD 2.9 billion by 2032, exhibiting a CAGR of 5.7% during 2024–2032.
Pneumococcal vaccines are administered to improve protection from the bacterium streptococcus pneumoniae, which can lead to meningitis, sepsis, and pneumonia. Two kinds of pneumococcal vaccines exist, specifically pneumococcal conjugate (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). These vaccines activate an individual’s immune system to create antibodies against the bacteria, ultimately preventing infection spread, lowering mortality rates, and avoiding emergency hospital visits.
Growth Factors and Opportunities:
The partnership of public and private sectors in broadening vaccine distribution networks presents a significant market opportunity in the projected timeframe. In addition, increased funding for product development has resulted in the development of more potent vaccines that focus on a wider variety of pneumococcal strains.
Key Participants:
Leading companies in the global market prioritize strategic acquisitions to enhance their R&D capabilities and gain a competitive advantage, allowing them to provide users with innovative products.
Some of the major players participating in the Europe pneumococcal vaccine market:
- Astellas Pharma Inc
- CSL Ltd
- GSK plc
- Merck & Co. Inc
- Panacea Biotech Ltd
- GPN Vaccines
- SK Bioscience
- Pfizer Inc.
- Sanofi S.A
- Serum Life Sciences Ltd
- Talley Group Ltd
- Walvax Biotechnology Co. Ltd
Market Segmentation:
The Europe pneumococcal vaccine market is mainly segmented based on type, product, end user, and country. Based on type analysis, in 2023, the pneumococcal conjugate vaccines dominated the market because of how well they work at stopping various pneumococcal illnesses, especially in young children and at-risk groups.
Moreover, according to the end user analysis, in 2023, the public sector segment accounted for a larger market share because of the increasing government efforts and national vaccination campaigns to put public health first. Support from global health organizations and projects dedicated to tackling pneumonia has enhanced government initiatives, leading to a greater need for pneumococcal vaccinations.
Europe Pneumococcal Vaccine Market, Technology Outlook (Revenue – USD Billion, 2019-2032)
- Butadiene Process
- Davy Process
- Propylene Oxide Process
- Reppe Process
- Other Processes
Europe Pneumococcal Vaccine Market, Application Outlook (Revenue – USD Billion, 2019-2032)
- Tetrahydrofuran (THF)
- Polybutylene Terephthalate (PBT)
- Gamma-Butyrolactone (GBL)
- Polyurethane (PU)
- Others
Europe Pneumococcal Vaccine Market, End-Use Outlook (Revenue – USD Billion, 2019-2032)
- Automotive
- Healthcare & Pharmaceuticals
- Textile
- Electrical& Electronics
- Others
Recent Developments in the Vaccine Industry:
- June 2023: SK Bioscience’s Phase II Clinical Trial Success for GBP410
SK Bioscience announced positive results from its Phase II clinical trials of the 21-valent pneumococcal conjugate vaccine candidate, GBP410, developed in collaboration with Sanofi. The successful trial results set the stage for advancing to Phase III trials in the first half of 2024, which could significantly contribute to pneumococcal disease prevention. - November 2023: GPN Vaccines and BioCina Extend Partnership
GPN Vaccines and BioCina extended their partnership to enhance the manufacturing capabilities for vaccines targeting meningitis, pneumonia, and febrile bacteremia. This collaboration aims to scale up the production of critical vaccines to address global health challenges, particularly in areas with high disease burden. - November 2022: Pfizer’s Positive Opinion from EMA for 20-Valent Vaccine
In November 2022, Pfizer announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for its 20-valent pneumococcal conjugate vaccine. This vaccine is designed to protect against a broader range of pneumococcal strains, offering expanded protection for individuals at risk of pneumococcal diseases.
Pneumococcal vaccination programs play a crucial role in preventing diseases caused by streptococcus pneumoniae, which lead to serious health issues such as pneumonia, meningitis, and sepsis. Most European countries include PCVs in their national immunization programs (NIPs), targeting primarily children under five and older adults.